PATENT CLAIM ANALYSIS

Application Number: 15754191
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-01
Patent Classification: ["514", "282000"]

Abstract:
The presently disclosed subject matter provides methods for inhibiting the growth and/or survival of bacteria from the  Borrelia  genus and for treating Lyme disease. These methods include agents that inhibit the glutathione/γ-glutamyl pathway and are involved in protection against free radical damage, cell membranes, energy production, and/or reactive oxygen species production. Many of these compounds are antimicrobial agents (antibiotics, antivirals, antifungals, anthelmintics or antiparasitics) and drugs used for treating other non-infectious conditions.

Claim (Index 6):
A method for inhibiting the growth and/or survival of bacteria from the  Borrelia  genus, the method comprising contacting bacteria from the  Borrelia  genus with an effective amount of at least one agent selected from the group consisting of verteporfin, thonzonium bromide, tetrachloroethylene, benzododecinium chloride, butyl chloride (1-chlorobutane), 3-formyl rifamycin, potassium antimonyl tartrate (tartar emetic), toltrazuril, thiostrepton, pyroglutamic acid, mepartricin, tilorone, oxantel, hycanthone, pyrimethamine, trilocarban (3,4,4\u2032-trichlorocarbanilide), carbenicillin, oltipraz, bitoscanate, sarafloxacin, bacitracin, dextrorphan tartrate, tetramisole, bifonazole, ethacridine lactate, zanamivir, aluminum lactate, p-arsanilic acid, nifursol, nevirapine, rifaximin, oxibendazole, metrifonate, indatraline, florfenicol, benznidazole, ganciclovir, tazobactam, oxfendazole, phenothiazine, flubendazole, midecamycin, fluconazole, docosanol, aztreonam, benzoylpas (4-Benzamido salicylic acid), trifluridine, undecylenic acid, closantel, cefixime, thiamphenicol, ricobendazole (albendazole oxide), sulfamoxole, clopidol, tosufloxacin, metampicillin, amikacin, lamivudine, cephalosporin C, sulfachlorpyridazine, lomofungin, artesunate, valacyclovir, carzenide (4-carboxybenzenesulfonamide), clinafloxacin, efavirenz, cefsulodin, cloxyquin (5-chloro-8-hydroxy-quinoline), symclosene (trichloroisocyanuric acid), didanosine (2\u2032-3\u2032-dideoxyinosine), floxuridine (5-fluorodeoxyuridine), cyacetacide, roxithromycin, oxiconazole nitrate, climbazole, protionamide, ribavirin, griseofulvin, rifamycin SV, salicylanilide, diclazuril, imiquimod, penciclovir, nystatin, ampicillin, puromycin, stavudine (2\u2032,3\u2032-didehydro-3\u2032-deoxythymidine), potassium iodide, voriconazole, penimepicycline, amantadine, nitroxoline (8-hydroxy 5-nitroquinoline), 4-aminosalicylic acid, ciclopirox olamine, nelfinavir mesylate, anisomycin, betamipron (n-benzoyl-b-alanine), famciclovir, flucytosine (5-fluorocytosine), clotrimazole, rimantadine, pazufloxacin, carbadox, amantadine, dibekacin, clorsulon, thiacetazone (amithiozone), fleroxacin, clofoctol, butoconazole nitrate, quinaldine blue, and methylene blue.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 88.0
- Lexical Diversity: 1.31746
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15799573', '15200657', '15539442', '15501469', '12676794']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6855253743393402
- 35 USC 102 Novelty (BERT): 0.487862865564569
- Combined Prediction Score: 0.6657591234618632
- Mean Citation Score: 165.459292
- Max Citation Score: 170.63629
- Similarity Product: 120.1975152027607

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test